Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote injection, for the treatment of acetaminophen poisoning; Caldolor injection, for the treatment of pain and fever, Kristalose for oral solution, a prescription laxative, for the treatment of constipation, and Omeclamox-Pak, oral, for the treatment of Helicobacter pylori infection and related duodenal ulcer disease. Its brands also include Sancuso transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia, and Vibativ injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia.
BörsenkürzelCPIX
Name des UnternehmensCumberland Pharmaceuticals Inc
IPO-datumAug 11, 2009
CEOMr. A. J. Kazimi
Anzahl der mitarbeiter91
WertpapierartOrdinary Share
GeschäftsjahresendeAug 11
Addresse1600 West End Avenue, Suite 1300
StadtNASHVILLE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl37203
Telefon18774842700
Websitehttps://www.cumberlandpharma.com/
BörsenkürzelCPIX
IPO-datumAug 11, 2009
CEOMr. A. J. Kazimi
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten